Abivax SA stock plunged sharply after the company disclosed results from the Phase 3 ABTECT maintenance trial for obefazimod late Monday evening. Shares fell 32.2% to trade at e278.60 as markets digested a mixed dataset that combined clear efficacy with an unexpected safety signal.
The trial results showed obefazimod met its endpoints, delivering what Abivax described as clinically meaningful efficacy and producing a remission rate of about 40% for both doses evaluated. At the same time, the dataset included cancer cases among patients receiving the higher dose. Abivax said the cancer cases were considered "unrelated to treatment by investigators, and no organ-specific clustering was observed," but that conclusion did not prevent a sharp market reaction.
Management said it plans to submit a New Drug Application to the U.S. Food and Drug Administration for obefazimod in ulcerative colitis in late Q4 2026, a regulatory step that remains on the company e2 80 99s timetable despite the trial e2 80 99s safety observations.
Analyst and market responses
Analyst commentary amplified the selloff. Jefferies downgraded Abivax from Buy to Hold and cut its price target to $90 from $160, citing the complications posed by the cancer signal observed in the pivotal trial. A Jefferies analyst said the "cancer signal complicates matters," adding that "even if unrelated noise, we think the overhang will be real, especially considering absence of other value-inflecting data events over the next [year]."
Not all research shops turned negative. Morgan Stanley kept an Overweight rating but trimmed its target from $145 to $132. Truist Securities retained a Buy recommendation while lowering its target from $140 to $135. Citizens continued to rate the stock Market Outperform and raised its target from $131 to $187. The range of responses illustrates divergent investor views on how the safety findings will affect Abivax e2 80 99s regulatory and commercial prospects.
Wider market context
The decline in Abivax shares was a company-specific event and did not reflect a broader pullback across equities. On the same day the S&P 500 gained 0.3%, the NASDAQ rose 0.4% and the Dow Jones Industrial Average added 0.1%, indicating a generally constructive backdrop for markets while Abivax moved in the opposite direction. The biotech sector did not record any sector-wide negative catalyst on the day.
Macro data were focused on upcoming jobs reports, with attention building toward Friday e2 80 99s May nonfarm payrolls and a set of job openings figures that could influence Federal Reserve policy expectations in coming sessions. Those macro dynamics were separate from the stock-specific drivers that pushed Abivax lower.
Financial position and outlook
Abivax also reported first-quarter 2026 financial results, noting cash on hand of e2491.6 million. The company said that level of liquidity is expected to fund operations into the fourth quarter of 2027. While the cash runway is a constructive element of the balance sheet, it was not sufficient to offset investor concerns stemming from the safety observations in the trial and the subsequent shift in analyst sentiment.
The combination of an unanticipated safety signal in a pivotal study and a high-profile analyst downgrade proved decisive in driving the intraday selloff. Abivax e2 80 99s efficacy results underscore potential therapeutic value, but the presence of cancer cases at the higher dose has complicated the investment thesis and created an immediate overhang for the stock.
At this stage, the company continues to position obefazimod for regulatory submission in late Q4 2026, while market participants weigh the implications of the trial e2 80 99s safety findings alongside the company e2 80 99s cash runway into late 2027.